ABSTRACT
Cisplatin and derivatives are commonly used as chemotherapeutic agents. Although the cytotoxic action of cisplatin on cancer cells is very efficient, clinical oncologists need to deal with two major difficulties, namely the onset of resistance to the drug and the cytotoxic effect in patients. Here, we used Caenorhabditis elegans to investigate factors influencing the response to cisplatin in multicellular organisms. In this hermaphroditic model organism, we observed that sperm failure is a major cause of cisplatin-induced infertility. RNA sequencing data indicate that cisplatin triggers a systemic stress response, in which DAF-16/FOXO and SKN-1/NRF2, two conserved transcription factors, are key regulators. We determined that inhibition of the DNA damage-induced apoptotic pathway does not confer cisplatin protection to the animal. However, mutants for the pro-apoptotic BH3-only gene ced-13 are sensitive to cisplatin, suggesting a protective role of the intrinsic apoptotic pathway. Finally, we demonstrated that our system can also be used to identify mutations providing resistance to cisplatin and therefore potential biomarkers of innate cisplatin-refractory patients. We show that mutants for the redox regulator trxr-1, ortholog of the mammalian thioredoxin reductase 1 TRXR1, display cisplatin resistance. By CRISPR/Cas9, we determined that such resistance relies on the presence of the single selenocysteine residue in TRXR-1.
This article has an associated First Person interview with the first author of the paper.
Footnotes
Competing interests
The authors declare no competing or financial interests.
Author contributions
Conceptualization: F.J.G.-R., E.N., A.M.-V., A.V., J.C.; Methodology: F.J.G.-R., C.M.-F., M.B., S.H.; Formal analysis: F.J.G.-R., D.B.; Investigation: F.J.G.-R., C.M.-F., D.B., D.K., X.S., S.H., J.C.; Writing - original draft: F.J.G.-R., J.C.; Writing - review & editing: F.J.G.-R., J.C.; Visualization: J.C.; Supervision: A.M.-V., A.V., J.C.; Funding acquisition: E.N., A.V., J.C.
Funding
This study was supported by grants from the Instituto de Salud Carlos III (ISCIII; PI15/00895 to J.C., PI16/01898 to A.V.), which is co-funded by the European Regional Development Fund/FEDER. The A.V. laboratory was also supported by funding from Ministerio de Economía y Competitividad (BFU2007-67123). M.B. was supported by a Netherlands Organization for Scientific Research (NWO) chemical sciences ECHO grant (711.014.005). E.N. was supported a Sociedad Española de Oncología Médica (SEOM) grant for emerging research groups. F.J.G.-R. was the recipient of a PFIS predoctoral fellowship from ISCIII. A.M.-V. was supported by a grant from Ministerio de Economía y Competitividad (BFU2015-64408-P, co-financed by the European Social Fund) and is a member of the EU-ROS Cost Action of the European Union. J.C., M.B., S.H. and A.M.-V are members of the GENIE EU Cost action. D.B. was recipient of a Consejo Nacional de Ciencia y Tecnología ‘al extranjero’ fellowship (523048).
Data availability
Raw data and details of RNA-sequencing experiments are available at NCBI GEO, with the reference GSE111654.
Supplementary information
Supplementary information available online at http://dmm.biologists.org/lookup/doi/10.1242/dmm.033506.supplemental
- Received January 8, 2018.
- Accepted April 10, 2018.
- © 2018. Published by The Company of Biologists Ltd
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.
Article navigation
Related articles
Cited by...
More in this TOC section
Similar articles
Other journals from The Company of Biologists
DMM and COVID-19
We are aware that the COVID-19 pandemic is having an unprecedented impact on researchers worldwide. The Editors of all The Company of Biologists’ journals have been considering ways in which we can alleviate concerns that members of our community may have around publishing activities during this time. Read about the actions we are taking at this time.
Please don’t hesitate to contact the Editorial Office if you have any questions or concerns.
Alessandro Bailetti is awarded the DMM Outstanding Paper Prize 2019
The annual prize is awarded to the first author of the paper that is judged by the journal’s editors to be the most outstanding contribution to the journal that year. Alessandro Bailetti's winning paper presents results that indicate a possible connection between E(Pc) and the Tip60 complex, and leukemia. Find out more about Alessandro and read the winning paper.
Find DMM online
We may not be meeting you in person this year, but we’re always here to chat about DMM and The Company of Biologists. Join the conversation over on Twitter, email us or catch Scientific Editor Julija Hmeljak at these upcoming virtual meetings:
MRC Human Genetics Unit (Virtual) Symposium: Aberrant Cell State Transitions in Human Disease
23-24 September
Genomic Imprinting – from Biology to Disease
28 September – 1 October
ZDMS Virtual webinar series
Throughout September – December
Interview - Mohd. Salman
First author Mohd. Salman studies traumatic brain injury. In an interview, he takes us through his latest research in DMM, explaining the potential implications of the findings, and discussing Wistar rats as a model system and life as a early-career researcher.
Call for papers - The RAS Pathway: Diseases, Therapeutics and Beyond
DMM invites you to submit original research for a special issue focused on targeting the RAS pathway. The submission deadline is 1 March 2021. Find out more and showcase your breakthrough research in this special collection.
It’s a time of turmoil for young scientists
“My students are my priority – they are on the brink of their careers.”
Dr Jodie Rummer (ARC Centre of Excellence for Coral Reef Studies at James Cook University) talks about the importance of her role as a supervisor in supporting graduate students and post docs financially, intellectually and emotionally during this period of uncertainty.